StockNews.com Begins Coverage on Agile Therapeutics (NASDAQ:AGRX)

StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRXFree Report) in a report issued on Monday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a hold rating on shares of Agile Therapeutics in a report on Monday, March 18th.

Get Our Latest Stock Report on Agile Therapeutics

Agile Therapeutics Price Performance

NASDAQ AGRX opened at $0.41 on Monday. Agile Therapeutics has a 52-week low of $0.20 and a 52-week high of $6.71. The business’s 50-day moving average price is $0.48 and its 200 day moving average price is $1.31. The firm has a market cap of $2.84 million, a P/E ratio of -0.04 and a beta of 1.25.

Agile Therapeutics (NASDAQ:AGRXGet Free Report) last announced its quarterly earnings data on Thursday, March 28th. The specialty pharmaceutical company reported ($1.46) earnings per share for the quarter. The business had revenue of $3.62 million during the quarter.

Institutional Trading of Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC raised its position in Agile Therapeutics, Inc. (NASDAQ:AGRXFree Report) by 10.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the period. Armistice Capital LLC owned approximately 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. 10.92% of the stock is currently owned by institutional investors and hedge funds.

About Agile Therapeutics

(Get Free Report)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Further Reading

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.